{"id":138016,"date":"2022-11-10T09:05:00","date_gmt":"2022-11-10T14:05:00","guid":{"rendered":"https:\/\/44.250.171.167\/?p=138016"},"modified":"2022-12-01T21:47:31","modified_gmt":"2022-12-02T02:47:31","slug":"valiant-organics-ltd-valiantorg-q2-fy23-earnings-concall-transcript","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/valiant-organics-ltd-valiantorg-q2-fy23-earnings-concall-transcript\/","title":{"rendered":"Valiant Organics Ltd (VALIANTORG) Q2 FY23 Earnings Concall Transcript"},"content":{"rendered":"

Valiant Organics Ltd (NSE:VALIANTORG<\/a>) Q2 FY23 earnings concall dated Nov. 10, 2022<\/span><\/strong><\/p>\n

Corporate Participants:<\/h2>\n

Nikesh Shetty<\/strong> — Investor Relations<\/em><\/p>\n

Arvind Kanji Chheda<\/strong> — Managing Director and Executive Director<\/em><\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

Analysts:<\/h2>\n

Varun<\/strong> — Kenia Capital — Analyst<\/em><\/p>\n

Adit Ketan<\/strong> — Smith Limited — Analyst<\/em><\/p>\n

Manish Jain<\/strong> — Money Life Advisory Service — Analyst<\/em><\/p>\n

Garo Shah<\/strong> — Harshad Gandhi Securities — Analyst<\/em><\/p>\n

Sachin Kasera<\/strong> — Swan Investments — Analyst<\/em><\/p>\n

Ashutosh Shirvaikar<\/strong> — Navi EMC — Analyst<\/em><\/p>\n

Unidentified Participant<\/strong> — — Analyst<\/em><\/p>\n

Ankur Shah<\/strong> — Quasar Capital — Analyst<\/em><\/p>\n

Dish PAPak<\/strong> — Vito Capital — Analyst<\/em><\/p>\n

Yugesh Tiwari<\/strong> — Arian Capital Markets Limited — Analyst<\/em><\/p>\n

Nikos Shape<\/strong> — — Analyst<\/em><\/p>\n

Presentation:<\/h2>\n

Operator<\/strong><\/p>\n

Good day, ladies and gentlemen, and welcome to the Q2 FY ’23 Earnings Conference Call of Welin Organics Limited, hosted by Edelweiss Broking Limited.[Operator Instructions]<\/p>\n

I now hand the conference over to Mr. Nikesh Shetty from Edelweiss Broking Limited. Thank you, and over to you, Mr. Sati.<\/p>\n

Nikesh Shetty<\/strong> — Investor Relations<\/em><\/p>\n

Thank you, Michelle. Good afternoon, everyone. On behalf of deli — we welcome you all to the Q2 and H1 FY ’21 Earnings Conference Call of Trilliant Organics Limited. We have with us today Mr. Arvind Kanji Chheda, Managing Director; Mahek Manoj Chheda, CFO and Executive Director; and Mr. Mihir Shah, Senior Finance Manager of the company. I would request the management for the opening remarks, post which we will open the floor for Q&A.<\/p>\n

So thank you, and over to you, sir.<\/p>\n

Arvind Kanji Chheda<\/strong> — Managing Director and Executive Director<\/em><\/p>\n

Thank you. Good afternoon, everyone. It is a pleasure to welcome you all at our earnings conference call for the second quarter of the finance Welcome, everyone, to this earnings call, and I would like to request our CFO, Mr. Mark Sara, to take you through the financial and operational highlights of the quarter. Thank you.<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

Thank you, and good afternoon, everyone, and welcome to this earnings call. I hope you had a chance to study our financial and earnings presentation, which have been uploaded on our website and exchanges. Let me start by briefing you on the company’s financial performance on a consolidated basis for the second quarter of the financial year ’22\/’23. The revenues from operations we grew by about 1% on a quarter-on-quarter basis and around 3% on a year-on-year basis to around INR264 crores. The EBITDA was reported at around which grew by around 31% quarter-on-quarter and degrew by around 11% on a year-on-year basis.<\/p>\n

Our EBITDA margin for the quarter was 15.87%. The net profit reported was around INR256 crores, which grew by about 52% quarter-on-quarter and decreased by 15% year-on-year. Our PAP margins for the quarter were 9.9%. For the half year ended, the revenue from operations stood at around INR530 crores, which grew by around 2.5% year-on-year with EBITDA declining by around 25% year-on-year to INR74 crores and EBITDA margin of 13.91%. The net profit stood at around crores, declining by 27% year-on-year and PAP margins for half yearly financial year ’23 stood at 8.02%. Coming to the operational highlights for the quarter under review.<\/p>\n

Despite several challenges, quarter two financial year ’23 closed on a positive note compared to the previous quarter. although the revenue declined marginally, profitability improved over the previous quarter. revenue degrowth was primarily due to the decline in chlorination revenues because of the fire incident at Sarigam in quarter one financial year ’20 EBITDA margin improved on a quarter-on-quarter basis due to raw material prices stabilizing.<\/p>\n

With regards to the PAP plant, production output on an average was about 365 metric ton in quarter two financial year ’23. And currently have crossed the 400 metric ton mark, and we are on track to achieve the target of 500 metric ton per month in the batch process by year-end. Pharma intermediaries project is completed with trial runs also done. The project is awaiting the approvals from the government authorities, and we expect to close by the end of quarter three financial year ’23.<\/p>\n

With this, we can now open the floor for question-and-answer session. Thank you.<\/p>\n

Questions and Answers:<\/h2>\n

Operator<\/strong><\/p>\n

Thank you very much. [Operator Instructions] We have the first question from the line of Varun [Phonetic] from Kania Capital. Please go ahead.<\/p>\n

Varun<\/strong> — Kenia Capital — Analyst<\/em><\/p>\n

Good afternoon, thank you for the opportunity. I just wanted to know the asset turns that we can expect from the recently commissioned AP as well as the pharma intermediates plant?<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

Good afternoon. So the — we’ve not commissioned it yet, both the…<\/p>\n

Operator<\/p>\n

Operator<\/strong><\/p>\n

Sorry to interrupt your sounding distant, sir.<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

Sorry, is this better?<\/p>\n

Operator<\/strong><\/p>\n

Yes, sir, please proceed.<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

Yes. So I was saying that we haven’t commissioned it yet, but once we commission the asset turns would be somewhere around 1x, and that is what we are assuming as of now, but we’ll know better once the operations start.<\/p>\n

Adit Ketan<\/strong> — Smith Limited — Analyst<\/em><\/p>\n

Okay. Thank you. And my second question is, like, historically, we like to we’ve aspired to grow 20% to 25%. So beyond the OEP and pharma intermediates or like in a two- to three-year horizon, what are the revenues that we are looking to get into or grow — so I just want a three-year perspective on here.<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

So I don’t have a three-year perspective, but giving immediate one-year perspective, we expect that will — so we had an incident in Sarigam because of which our top line also has been affected. So we believe that by year end, we would somewhere grow by 5% to 10%, somewhere in the INR1,000 crores to INR1,100 crores stand-alone basis. And the year after that, somewhere around 30% is what we expect to grow once PAP fully comes online as well as OAP and pharma intermediaries.<\/p>\n

Adit Ketan<\/strong> — Smith Limited — Analyst<\/em><\/p>\n

Okay. So next year, you’ll be able to do a better view.<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

Correct.<\/p>\n

Varun<\/strong> — Kenia Capital — Analyst<\/em><\/p>\n

Thank you. That’s all for me.<\/p>\n

Operator<\/strong><\/p>\n

Thank you. [Operator Instructions] we have the next question from the line of Adit Ketan from Smith Limited. Please go ahead.<\/p>\n

Adit Ketan<\/strong> — Smith Limited — Analyst<\/em><\/p>\n

Yes. Thank you. Sir, my first question is on to the margin trend. So on a quarter-on-quarter basis, there is an improvement in the margin. So for the current quarter, they are at 17%. However, our half yearly margins are or are around 14%. So with the raw material prices now stabilizing, so can we expect the full year margins to be around like 18% to 19%?<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

Yes. So the — we are definitely expecting an improvement in the margins. Unlike Q1, the Q2 was better, and we believe Q3, Q4 will also be better. Having said that, on a full year basis, we may be dragged down by the Q1 margin overall on the average, but we are expecting to be somewhere around 17%, 18%.<\/p>\n

Adit Ketan<\/strong> — Smith Limited — Analyst<\/em><\/p>\n

Okay. Okay. And how is the trend of the raw material prices like the final and the PMC — so considering — so they have stabilized now or they are still in declining more<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

They’ve softened by now. They have also been stabilizing. So we don’t expect it to reduce further. We are probably at that close to the bottom pricing.<\/p>\n

Adit Ketan<\/strong> — Smith Limited — Analyst<\/em><\/p>\n

Okay. And on to the hydrogenation business, so we were planning some sort of INR150 crores of capex into OP and expanding some of the down — so backward integrated capacity. So that has been completed or still we are<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

So for OA, it’s still — we are still doing trial runs and there is some bit of capex that will still further get into it. So that is still ongoing. Pharma intermediaries, which is again in the hydrogenation plant itself, that capex is done.<\/p>\n

Adit Ketan<\/strong> — Smith Limited — Analyst<\/em><\/p>\n

And apart from we were also planning some sort of other like of peers, some sort of…<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

No. I think you’re referring to OA and PA, that was already done and commissioned a year and half back.<\/p>\n

Adit Ketan<\/strong> — Smith Limited — Analyst<\/em><\/p>\n

There has been already commissioned.<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

Yes, yes. Okay.<\/p>\n

Adit Ketan<\/strong> — Smith Limited — Analyst<\/em><\/p>\n

And on to this pharma intermediates business, so this would be completely — so given as a captive to RP Parmalen?<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

Yes, that’s correct.<\/p>\n

Adit Ketan<\/strong> — Smith Limited — Analyst<\/em><\/p>\n

And on to the PAP front, so is there any update? So like is there any plan to now shift from batch process to continuous process? Anything has been like so we have achieved some success over the there?<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

No. So the trials are going on for that. But currently, we are focusing on getting to the full capacity of batch which we almost close to achieving that 500 target we crossed 400 in the current month. And going forward, by the end of the year, we’ll reach 500 also. Simultaneously, there will be trials to increase that capacity and make it continuous. But as of now, we are more focused on getting to the maximum capacity in the batch process.<\/p>\n

Adit Ketan<\/strong> — Smith Limited — Analyst<\/em><\/p>\n

So this 500 metric tons per month, so this would be achieved by the year-end. — thereafter, we can shift to continuous process<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

We are trying to achieve that. We — I will not make a definitive statement on that, but that is what we are trying to achieve.<\/p>\n

Adit Ketan<\/strong> — Smith Limited — Analyst<\/em><\/p>\n

Okay. Okay. And for the Sarigam incident we-<\/p>\n

Operator<\/strong><\/p>\n

[Operator Instructions] We have the next question from the line of Manish Jain from Money Life Advisory Services. Please go ahead.<\/p>\n

Manish Jain<\/strong> — Money Life Advisory Service — Analyst<\/em><\/p>\n

Thank you for the opportunity. My first question is, what has been the capacity utilization across our plant this quarter?<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

Okay. And the next question.<\/p>\n

Manish Jain<\/strong> — Money Life Advisory Service — Analyst<\/em><\/p>\n

Next year, sir, what has been the hindrance in shifting to continuous process from that process for the PAP plant?<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

Sorry, can you repeat the second question?<\/p>\n

Manish Jain<\/strong> — Money Life Advisory Service — Analyst<\/em><\/p>\n

Yes. My question is, what has been the problem in shifting to continuous process from batch process in the PAP plant?<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

Okay. So on the question one, we were at a utilization of around but that is given that we considered Unit two as 1,000 tons capacity and — if I change that, then our overall utilization for the company is somewhere around 68% to 70%.<\/p>\n

Manish Jain<\/strong> — Money Life Advisory Service — Analyst<\/em><\/p>\n

Okay. The second question<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

And on the second one on the second one, we are facing the same problem that we faced initially, the product stabilization and the quality that we require is not coming through in the continuous one. So we are trying to resolve that that is the issue.<\/p>\n

Manish Jain<\/strong> — Money Life Advisory Service — Analyst<\/em><\/p>\n

Okay. And lastly, I wanted to understand the rising other expenses this quarter?<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

So other expenses this quarter, the raw material — sorry, the other expenses, it has decreased to — it has increased to a certain extent. I think, about 5% to 6% increase out of which major increase was in consumption in power, there was some bit of increase in labor cost. And and some freight and freight and forwarding charges. So these were the major increases in the other income and EPP.<\/p>\n

Manish Jain<\/strong> — Money Life Advisory Service — Analyst<\/em><\/p>\n

Okay. Thank you.<\/p>\n

Operator<\/strong><\/p>\n

Thank you. We have the next question from the line of Garo Shah from Harshad Gandhi Securities. Please go ahead.<\/p>\n

Garo Shah<\/strong> — Harshad Gandhi Securities — Analyst<\/em><\/p>\n

Hi. Thanks a lot for the opportunity. So Mike, I have a couple of questions. Both are on PAP. So just wanted to understand the pricing environment for our pay product, — and second one, I think if you consider last two quarters, we are hearing the same like comments from you guys on the technical difficulty you are getting into PAP. So can you provide some like honest flat’s the exit thing? And do you think by quarter four, we should be able to like solve all our problems as far as PAP is concerned? Thanks.<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

So on the pricing front, PAP prices have also reduced from quarter-on-quarter. It has almost reduced by 100 on an average. So there is a reduction. — simultaneously, there’s a reduction in our raw material costs also. So that’s on the PAP pricing bit. On the second question of yours, I think I understand that we do have that same problem and we are repeating because that is the actual scenario. We are trying our level best to achieve the quality, but we are not being able to so far. So the statement satisfy remains the same. — we are trying. So like I said, I can’t definitively say that we’ll start the continuous in April, but we still have six or five months to go, we are trying our level best to work things out and get that stability. We achieved it in batch. We are trying to do the same in continuous.<\/p>\n

Garo Shah<\/strong> — Harshad Gandhi Securities — Analyst<\/em><\/p>\n

Okay. Thanks.<\/p>\n

Operator<\/strong><\/p>\n

Thank you. [Operator Instructions] We have the next question from the line of Sachin Kasera from Swan Investments. Please go ahead.<\/p>\n

Sachin Kasera<\/strong> — Swan Investments — Analyst<\/em><\/p>\n

Thanks giving the opportunity. So in terms of the cost of manufacturing and the margins, what are the key differentiating factors between the batch versus the continuous process as far as PEP is concerned?<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

So it’s the economies of scale that improves the quantity increases, and that’s the only difference that we can achieve from continuous — batch to continue. And the time of the real. So there is more time that go into batch than putting the other batch loading and loading, which in continuous gives that time efficiency.<\/p>\n

Sachin Kasera<\/strong> — Swan Investments — Analyst<\/em><\/p>\n

So in the presentation, you mentioned that you’re targeting 500 tons per month in the batch process. What are the type of in case we are commercially successful? What is the type of volume we can do as we move to a continuous process per<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

Around 1,000 metric tons.<\/p>\n

Sachin Kasera<\/strong> — Swan Investments — Analyst<\/em><\/p>\n

Okay. So — and the yield and the quality is the more or the same? Or there’s some difference also in unit continues<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

No, no. So once we move to continuous, there’s no difference between the yield of final product, but the difference right now that we are facing is that we’re not getting the yield and continuous. So we are not moving it. But once — so I think your question is whether we make it by batch or by continuous — does the product remain the same, then yes, the product and the yield remains the same.<\/p>\n

Sachin Kasera<\/strong> — Swan Investments — Analyst<\/em><\/p>\n

Okay. Okay. Second question was on this — I think you mentioned briefly, but if you could tell us what type of utilization we can see in this pharma intervened in the next financial year? Because I think this year, we are just starting FY ’24 and FY ’25, what type of utilization you are visualizing for the farm in termites? And do we foresee any challenges on the technical front, the way we face in PAP, arena?<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

So I think we’ll probably be at around 45%, 50% in the initial quarters. And then by the end of next year, we could aim at full utilization?<\/p>\n

Sachin Kasera<\/strong> — Swan Investments — Analyst<\/em><\/p>\n

And what is the revenue at full utilization you can expect from this plant?<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

We are expecting it to be somewhere around INR50 crores.<\/p>\n

Sachin Kasera<\/strong> — Swan Investments — Analyst<\/em><\/p>\n

Close. Okay. And any sense you can give us in terms of your overall capex for the current financial year and the next financial year?<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

So for the current financial year, we are expecting to do a total capex of somewhere around INR100 crores out of which we are through by about 50% in this quarter. And — for the year after, we are still analyzing. We are waiting for PAP to stabilize and pharma and OEP if they start then we’ll look at other opportunities of where we can put the capex. Otherwise, for now, the focus is there. So we’ve not gone into the analyzing of where it will go. But we are looking at some new products that are on the drawing table as of now. that may not have a significant capex but could be somewhere around INR40 or INR45 crores odd, if at all, it does get successful.<\/p>\n

Sachin Kasera<\/strong> — Swan Investments — Analyst<\/em><\/p>\n

Sure. If I look at our track record, we always reported return on capital in excess of 40%, closer to 60. It’s only 21 and 22 that we saw some relation because of these new investments and some challenges on BP. How do you see — do you see that the things are shaping up in FY ’24 and ’25 you can again start inching up to the 40% type of ROC level? And secondly, when you are evaluating some of these projects, what type of IRRs or ROCs you look at before you go ahead into the project?<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

So we definitely expect to improve our ROCs. — not — honestly, I don’t know whether we get back to the earlier historic ROCs because we still have to analyze that because we are right now in the middle of many other capex — many other projects that are trying to complete. But we aim to reach them. And what was your second question, I’m sorry?<\/p>\n

Sachin Kasera<\/strong> — Swan Investments — Analyst<\/em><\/p>\n

What is the type of IRS we look at before we go ahead with any large project.<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

So we don’t really have a threshold IRR. We generally look at two things. One is if the product is high in demand and there is an input substitution opportunity, — so if there’s an import substitute that we can replace by domestic production. That is one thing. And secondly, if there can be any backward forward integration within the company. So those are the actual two main criteria that we look at and then we build around it. But in terms of a threshold IRR, we don’t generally keep that threshold or we are flexible on that as far as we think that the opportunity is good.<\/p>\n

Sachin Kasera<\/strong> — Swan Investments — Analyst<\/em><\/p>\n

Sure. Great. Thank you.<\/p>\n

Operator<\/strong><\/p>\n

Thank you. We have the next question from the line of Adit Ketan from Smith Limited. Please go ahead.<\/p>\n

Adit Ketan<\/strong> — Smith Limited — Analyst<\/em><\/p>\n

Yes. thank you for the opportunity. My question was on to the Sarigam incident. So for the last two quarters, we are witnessing that the volumes have been impacted. So this incident was for a period of six months?<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

No, no. So there are two things. One is that it got impacted because of the gas. Second is when you — when the plant is not operational and then when you start, it doesn’t really start, it starts also in a phased manner. So it takes a couple of weeks to really stabilize. And third is the order book also that there are certain orders that need to be fulfilled. So the the customers and also there’s a bit of lag. And overall, the market demand has been affected in Europe, which is — so Sarigam is mainly our exports. So that global demand has also reduced. So we’ve not been able to do a full utilization in past — in the previous quarter.<\/p>\n

Adit Ketan<\/strong> — Smith Limited — Analyst<\/em><\/p>\n

So what is the current status? So have we like improved the utilization as compared to Q2? Or is it at the similar level<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

We have we have improved all the previous, but we are also looking at the demand to work up. So once that increases, we’ll again scale up our capacity. — as far as capability to scale up is concerned, that is fine. So that is behind us.<\/p>\n

Adit Ketan<\/strong> — Smith Limited — Analyst<\/em><\/p>\n

Okay. Focus on flotation actually, so that is majorly used for the agro chemicals, pharmaceuticals, cosmetics and veterinary industries — so which set of industries are feeling the pain in terms of demand, as you mentioned.<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

Agro. Mainly agro. Yes, mainly. Okay. Okay.<\/p>\n

Adit Ketan<\/strong> — Smith Limited — Analyst<\/em><\/p>\n

And for the last two quarters, so this segment is actually contributing 17% of revenue. So previously, so when there was a normalized situation, it used to also contribute around 3% to 4% — so when the volumes would — so would kick in. So can we expect it to again go to around 4%<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

So it will not go beyond because even PAP is getting scaled up. So that will also come into the mix, OEP will also come into the mix. So it means also hydrogenation as a chemistry will be on the top in terms of contribution of revenue. But yes, from current ’17, it will definitely be — it will go up.<\/p>\n

Adit Ketan<\/strong> — Smith Limited — Analyst<\/em><\/p>\n

Okay, okay. And just one last question. So now I believe onto the OAP front and the pharma intermediates also. So by next quarter, I believe, so we would be in a position to start the production from these plants — so now what is the next leg of capex, which the company is focusing on?<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

So like I said earlier, we are focusing on this — these three projects to really start and build up. Once that comes in, our next leg of capex will come. So probably another quarter or two, and I probably will be able to give you a better comment on this.<\/p>\n

Adit Ketan<\/strong> — Smith Limited — Analyst<\/em><\/p>\n

Okay. But but just to add up–<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

On a generalized basis, we do — we do a capex of 80 to 100 on an annual basis.<\/p>\n

Adit Ketan<\/strong> — Smith Limited — Analyst<\/em><\/p>\n

INR100 crores.<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

Yes.<\/p>\n

Adit Ketan<\/strong> — Smith Limited — Analyst<\/em><\/p>\n

Okay. Thank you.<\/p>\n

Operator<\/strong><\/p>\n

Thank you. We have the next question from the line of Ashutosh Shirvaikar from Navi EMC. Please go ahead.<\/p>\n

Ashutosh Shirvaikar<\/strong> — Navi EMC — Analyst<\/em><\/p>\n

Hi. Thanks for the opportunity. The question is the similar to the last question<\/p>\n

Operator<\/strong><\/p>\n

What a lot of disturbance from your line. May I request you to please use your hand set.<\/p>\n

Ashutosh Shirvaikar<\/strong> — Navi EMC — Analyst<\/em><\/p>\n

Yes, just hold on a second.<\/p>\n

Operator<\/strong><\/p>\n

Ladies and gentlemen, the line of Mr. Service is disconnected. We move on to the next participant. And the question is from the line of a from [Indecipherable] Mount Intra Finance Private Limited. Please go ahead.<\/p>\n

Unidentified Participant<\/strong> — — Analyst<\/em><\/p>\n

Hello. Yes. Sir, can you share some light on the particular EBITDA margin of your three segments in terms of chemistry, like tornation, hydrogenation and mines. So any like how to understand that, like is there a significant difference in the chemical process in terms of margin? This is the first question.<\/p>\n

Arvind Kanji Chheda<\/strong> — Managing Director and Executive Director<\/em><\/p>\n

On the<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

Your voice vent<\/p>\n

Operator<\/strong><\/p>\n

Mr. Sarkar, your audio is audible. Can you please use your handset<\/p>\n

Arvind Kanji Chheda<\/strong> — Managing Director and Executive Director<\/em><\/p>\n

Yes, yes.<\/p>\n

Unidentified Participant<\/strong> — — Analyst<\/em><\/p>\n

Yes,<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

So I heard your first question, if you could give you a second question.<\/p>\n

Unidentified Participant<\/strong> — — Analyst<\/em><\/p>\n

Yes. So am I audible now?<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

Yes.<\/p>\n

Unidentified Participant<\/strong> — — Analyst<\/em><\/p>\n

Yes. So what I was asking, like, if you can guide us regarding the difference in EBITDA margin, in terms of profitability in our three main chemistry basically, like chlorination, hydrogenation and on leases, like what is the difference in terms of margin in these three kind of processes?<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

Sure. So we don’t give out the margin for the each chemistry. But just on the guidance side, chlorination is on a higher side as a margin and then hydrogenation amorts are at a similar level.<\/p>\n

Unidentified Participant<\/strong> — — Analyst<\/em><\/p>\n

Okay. So chlorination is essentially a higher-margin business?<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

Yes.<\/p>\n

Unidentified Participant<\/strong> — — Analyst<\/em><\/p>\n

Okay. So like, sir, in that case, like if you see — if I track your volume, which you have shared, like on a year-on-year basis, like codination volume is down to from INR4,200 to almost INR196. So is that like one of the major reasons for our drop in margin? And once this recovered, particularly after your planned opening, like we can improve some improvement in blended margin from that respect.<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

Yes. So my Q1 margins were definitely impacted because of the incident at Sarigam and because of which the margins were impacted. But at the same time, raw material pricing were also volatile at that time. now the raw material rising is stabilizing, so that will have an impact, which will have a positive impact now on the margin. So multiple factors that played a role, it was not only the volumes of chlorination going down.<\/p>\n

Unidentified Participant<\/strong> — — Analyst<\/em><\/p>\n

Perfect. Sir, can you, like, one, year-on-year basis, our menus margin like volume is also stagnant or margin, it has come down. So can you help on that respect like when we can expect a pickup with that? Or like which are the products like when we will add so that our [Indecipherable] volume will go up<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

Dyes and pigments as an industry is also facing low demand. So because of that, volumes have seemed to stagnated or going down. But as and when textile industry improves, dyes and pigments will also improve and that is when we’ll see some improvement there. But it’s market driven. I do I cannot comment exactly when that will happen.<\/p>\n

Unidentified Participant<\/strong> — — Analyst<\/em><\/p>\n

Okay. So in that case, like M&A is, is it basically — this is a function of our picking out of the textile industry and particularly dyes and pigments.<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

Correct.<\/p>\n

Unidentified Participant<\/strong> — — Analyst<\/em><\/p>\n

Perfect. Okay. That’s all.<\/p>\n

Operator<\/strong><\/p>\n

Thank you. We have the next question from the line of Ankur Shah from Quasar Capital. Please go ahead.<\/p>\n

Ankur Shah<\/strong> — Quasar Capital — Analyst<\/em><\/p>\n

Congrats on the margin rebound. Just actually extending on the previous questions, like it seems like a demand problem — because if I just think about the chlorination volumes, they have seen a significant — obviously, there is, I think, a 2025 day hit, which was there because of the plant closure. But for me, can you give us some volume guidance or a volume sort of a scenario? Because from four to five to six to 962, is it possible for us to sell back?<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

Yes. So by fourth quarter, we’ll be back to the original volumes for Sarigam.<\/p>\n

Ankur Shah<\/strong> — Quasar Capital — Analyst<\/em><\/p>\n

Okay. So around INR4,000 crores, INR4,500 or for a quarter. Okay. And like, can you give us some idea because what I understand from a manufacturing of a chemical plant perspective is that the last 20% capacity utilization becomes a major turn of your profit because of the operational leverage which the plant gives. So is it the fact that the utilization levels are so low because obviously, chloropene is very profitable and the main product as of now. So is it that the margins are severely distressed like or, let’s say, not severely but you are distressed. In comparison, if suppose we run the plant at a INR4,000 crore<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

So let me tell you, yes, that is true to reach the last leg on the capacity. It is difficult, and it is — that is where the profitability lies. So just to give you some understanding, if you look at our previous years, chlorination has been — FY ’22 was 90-plus utilization even even monies were somewhere around 85%, 90% utilization. So we have achieved those utilizations. But currently, because of lower demand, we are not able to achieve that utilization. So that is the reason. But once the demand stabilize once the demand picks up, we’ll be able to again move from 60%, 65% utilization back to around 80, 85 type of utilization?<\/p>\n

Ankur Shah<\/strong> — Quasar Capital — Analyst<\/em><\/p>\n

Okay. Okay. So in this particular product, because even if I see the volume at the, obviously, the revenue is slightly insignificant, but loreationmonolis is, other — like is there a good — like decent visibility that, let’s say in two quarters’ time, we will be able to scale back to decent utilization levels? Because that will solve a lot of problems for us.<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

Correct. So as far as chlorination is concerned, a lot of it is dependent on the export markets and given the situation in Europe and the the geopolitical issue. That is why the demand is not picking up now. I really cannot give any kind of comment on when that will improve. But it is mainly based on that. once that demand picks up, we will be — we will scale up and meet those demands. And then it will be back to normal, but I really cannot give a definitive time period as to when that’s going to improve.<\/p>\n

Ankur Shah<\/strong> — Quasar Capital — Analyst<\/em><\/p>\n

So it’s not particularly because of competitive intensity, right? It is just that the end demand has fallen and it’s not that we are losing wallet share or anything of that sort, right?<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

No, no. You are right.<\/p>\n

Ankur Shah<\/strong> — Quasar Capital — Analyst<\/em><\/p>\n

Okay. Okay. Then like coming to the financials, what I understand is because a large part of our volume is export related, at least in the plurination PAPh what I understand is the freight cost and the container cost and everything has been coming down incrementally. So do we see any tailwinds over there, again, from a cost-saving perspective<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

Yes. So they are improving, you’re right. So that will be a tailwind going forward, while it will improve. So that is why our margins have also improved because all these costs have gone down.<\/p>\n

Ankur Shah<\/strong> — Quasar Capital — Analyst<\/em><\/p>\n

Okay. So that is already into the price for this quarter?<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

Yes.<\/p>\n

Ankur Shah<\/strong> — Quasar Capital — Analyst<\/em><\/p>\n

Okay. Okay. And lastly, on the debt front, I understand that we have come down slightly come down on the debt front from March level. But like — still from a working capital annual and it seems slightly uncomfortable or stretched — so what are your thoughts on that? Because it’s not great to have this stretch for — because again, with the volume increasing, this is going to go up again.<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

So yes, but we have improved from March to date. So we have come down on our short-term borrowing, but working capital was a problem because the incident happened at align Sarigam is also the good cash flow business. So that was an impact that we had and also the raw material costs were high at that time. So we face the issue with working capital. But with all that stabilizing, we believe going forward, next two quarters will be an improvement.<\/p>\n

Ankur Shah<\/strong> — Quasar Capital — Analyst<\/em><\/p>\n

Okay. Okay. And like just suggest, and I don’t know.<\/p>\n

Operator<\/strong><\/p>\n

[Operator Instructions] We have the next question from the line of Dish PAPak from Vito Capital. Please go ahead.<\/p>\n

Dish PAPak<\/strong> — Vito Capital — Analyst<\/em><\/p>\n

Yes. Thank you for the opportunity. On the slide, I’m seeing the ongoing capex, which is yet to commission of this OEP and pharma intermediates. — where the capex is being mentioned as INR156 crores, INR75 crores. And then if I’m reading this side and on the consol balance sheet, there is a CWIP of INR135 crores. And other projects as per the slide have already commissioned. So maybe I’m not able to understand promo, but can you just help me understand this CDP on the balance sheet is related to that<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

So CWIP on this — so pharma intermediates is approximately 60%. It may be somewhere so there that there could be a little bit of an overrun there, not anything significant. So that is a project which has the maximum part in the CWIP. So out of the INR132 crores, I’m talking on a stand-alone basis, out of the INR132 crores about about 65 was closed would be pharma intermediates. — and there are others. So there are other ETP and some other small small works that has been taken up. That is also playing a part in this. So<\/p>\n

Dish PAPak<\/strong> — Vito Capital — Analyst<\/em><\/p>\n

Pharma intermediates total project mentioned on the side is INR60 crores, which is already INR65 crores is already spent. So almost you’ve spent the entire capex on pharma and committed to spend, right? — so the OP will be 15. So this is..<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

So — so just plant and machinery is actually 15%. There is a building and other things also which come into? And if not simply OAP. So that is the CWIP that is there.<\/p>\n

Dish PAPak<\/strong> — Vito Capital — Analyst<\/em><\/p>\n

So maybe the numbers mentioned in the presentation are not. Maybe when you presented you can present it in.<\/p>\n

Arvind Kanji Chheda<\/strong> — Managing Director and Executive Director<\/em><\/p>\n

Correct.<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

So minutes will have some change and OP will also have some change.<\/p>\n

Dish PAPak<\/strong> — Vito Capital — Analyst<\/em><\/p>\n

Okay. And because there’s almost 2x difference between what is in the presentation and what is the CIB. Coming back to the other question, sir, this — so fluorination products are lesser demand. Just on this — just for my benefit, if you can just help me understand on the slide five, we have given key products and enduser industries of pharma and cosmetic impact — so on the face of it, don’t seem to be like too much in distress, but individual products might have some lands in terms of its specific application. So within culination, what are the larger products — and what it exactly is the end user industry having issues from a demand point of view, you can give more granular Understand in main issues are with agro and textile. So chlorination is agrochemical, but export-driven, so that is because of the global demand where the issue is. ith the chlorination. So which product within cchlorinationis agri and export driven. There are four or five products you mentioned, PCP or CP to 4D<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

Yes. So no, unfortunately, I won’t be able to disclose that information as to which product goes where but I can just give you a broad level that agro, which forms the most biggest part of our chlorination is where the demand issue is.<\/p>\n

Dish PAPak<\/strong> — Vito Capital — Analyst<\/em><\/p>\n

But there will be some specific molecule issue within ad, but Agrate doing quite okay globally.<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

And it’s — like I said, the export market is the issue.<\/p>\n

Dish PAPak<\/strong> — Vito Capital — Analyst<\/em><\/p>\n

There’ll be some molecule specific or<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

It’s proprietary, so I cannot tell you the specific.<\/p>\n

Dish PAPak<\/strong> — Vito Capital — Analyst<\/em><\/p>\n

But is that a structural issue with the product that molecule has got market share<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

No, this product — these products have been in the business surveillance. We’ve been doing this since 2000. So it’s almost two decades back, and these are the same molecules and products that have been there so far. So it’s not the molecules which are of the issue. Is that market demand that is of the issue.<\/p>\n

Dish PAPak<\/strong> — Vito Capital — Analyst<\/em><\/p>\n

And which geography is the geometry specific issue?<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

Mainly Europe.<\/p>\n

Dish PAPak<\/strong> — Vito Capital — Analyst<\/em><\/p>\n

Sure. Okay Europe. So that is agro. What is the issue with the local issue?<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

The local issue is the textile, which is monolesis and hydrogenation, both the products. So with textile, it’s the Dyson pigment. So our only products if you see for go into Dyson pigments and our hydrogenation also goes into Dyson pigments mainly. So both these two chemistries are affected because of the domestic textile — so our Dyson pigments is the textile dyes. So it’s linked to the textile business — textile industry.<\/p>\n

Dish PAPak<\/strong> — Vito Capital — Analyst<\/em><\/p>\n

Okay. Thank you, sir.<\/p>\n

Operator<\/strong><\/p>\n

[Operator Instructions] We have the next question from the line of Yugesh Tiwari from Arian Capital Markets Limited. Please go ahead.<\/p>\n

Yugesh Tiwari<\/strong> — Arian Capital Markets Limited — Analyst<\/em><\/p>\n

Thanks and good afternoon. My first question is basically on the raw material front. So just wanted to –<\/p>\n

Operator<\/strong><\/p>\n

Mr. Tiwari, I would request you to keep your mic a little bit far from your mouth because there is an Aerie disturbance, which we can hear.<\/p>\n

Yugesh Tiwari<\/strong> — Arian Capital Markets Limited — Analyst<\/em><\/p>\n

Is it better now?<\/p>\n

Operator<\/strong><\/p>\n

Yes, please proceed.<\/p>\n

Yugesh Tiwari<\/strong> — Arian Capital Markets Limited — Analyst<\/em><\/p>\n

Yes. So sir, my first question was on the raw material front. So just wanted to understand what would be our dependency on China in terms of raw materials?<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

Not at all. We are — most of our key raw materials are sourced within the group. And then there is a final, which is a commodity product, which is standard globally.<\/p>\n

Yugesh Tiwari<\/strong> — Arian Capital Markets Limited — Analyst<\/em><\/p>\n

And like we import final?<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

The import final, yes.<\/p>\n

Yugesh Tiwari<\/strong> — Arian Capital Markets Limited — Analyst<\/em><\/p>\n

Which region basically?<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

Across countries. So it’s a very standardized product. So wherever we get the best price, we do it. So it’s not really an issue from which country it comes.<\/p>\n

Yugesh Tiwari<\/strong> — Arian Capital Markets Limited — Analyst<\/em><\/p>\n

Sure. And in terms of the earlier question on the continuous process on — so when we tell that we’ll get the benefit of economy of scale, do we mean that the capacity utilization of the plant will increase because of that?<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

No. So in batch process, at 500, we are 550, we’ll be able to achieve 500 and continuous, which is 1,000 we’ll be able to achieve close to 2,000. So — as far as utilization is concerned, that will not be an issue. It’s just that our volumes will increase and time will decrease. So from that aspect, we’ll get benefit of more production.<\/p>\n

Yugesh Tiwari<\/strong> — Arian Capital Markets Limited — Analyst<\/em><\/p>\n

Yes. But that will only come in the next financial year, right? This financially, we are targeting only for batch process<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

On batch. Correct.<\/p>\n

Yugesh Tiwari<\/strong> — Arian Capital Markets Limited — Analyst<\/em><\/p>\n

And one more follow-up on the PAP. So it’s like both PAP prices and the raw material prices are declining. So just wanted to know about what is the cherry where any pricing? Do we have a fixed spread between raw material and a PAP when we price the product. Is there a specific spread between the raw material and the PAP prices?<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

So we are in that range. We try to meet our pricing for PAP at China level. And with that, we get to have that incremental a little bit of benefit. Apart from that, with both the raw material pricing going down, the margins more or less remained similar.<\/p>\n

Yugesh Tiwari<\/strong> — Arian Capital Markets Limited — Analyst<\/em><\/p>\n

And sir, lastly, on the agrochemical and demand decline in Europe. So just wanted to understand, is it because of some agrochemical molecules being banned in Europe? Or is it more like<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

No, it’s a geopolitical issue. Is the war the energy crisis and Europe getting affected overall because of that, and that is why the demand is down.<\/p>\n

Yugesh Tiwari<\/strong> — Arian Capital Markets Limited — Analyst<\/em><\/p>\n

Sure. And sir, lastly, on the pharma intermediates, which we are coming up the margins of these intermediates would be in the range of the consolidated margins for the company? Or it will be margin accretive better?<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

It will be standard. It will be at the company level<\/p>\n

Yugesh Tiwari<\/strong> — Arian Capital Markets Limited — Analyst<\/em><\/p>\n

Sure. Thank you sir. That is all for my queue.<\/p>\n

Operator<\/strong><\/p>\n

Thank you. [Operator Instructions] We have the next follow-up question from the line of Sachin Kasera from Sun Investments. Please go ahead.<\/p>\n

Sachin Kasera<\/strong> — Swan Investments — Analyst<\/em><\/p>\n

Yes. Just two questions. What is the type of revenue loss we had because of Sarigam — or if you could quantify like from September to March quarter when you expect to come back to full production, what is the incremental revenue we can expect from Sarigam.<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

I think — so on the loss side, quarterly, we’ll probably be somewhere around 15% to 20% of impact.<\/p>\n

Sachin Kasera<\/strong> — Swan Investments — Analyst<\/em><\/p>\n

On the EBITDA or the top line?<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

No, on the top line. For the EBITDA we are not allowed to disclose. Sorry.<\/p>\n

Sachin Kasera<\/strong> — Swan Investments — Analyst<\/em><\/p>\n

Sure, sure. That’s fine. And you mentioned about some 17% margin that was for the second half of the financial year? That was the indication for the full financial<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

We are hoping that it will be for the entire year. We are assuming that Q3 and Q4 will be better than Q2. And — but overall, on an average, we may stand somewhere around 17%.<\/p>\n

Sachin Kasera<\/strong> — Swan Investments — Analyst<\/em><\/p>\n

Because we have done close to 12.5%, 13% in the first half, approximately<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

The Q1 will probably bring us down, but we are hoping Q3 and four would be much better margins than our current margin level.<\/p>\n

Sachin Kasera<\/strong> — Swan Investments — Analyst<\/em><\/p>\n

And you think what wherever improvement we will see in Q3, Q4 that should sustain going ahead, there will be more like a sustainable margins? Or are you seeing some one-off benefits coming to in the second half?<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

No, no, that will be the sustained margin. So we’ll be seeing improvement because of raw material costs that has stabilized and then that will continue.<\/p>\n

Sachin Kasera<\/strong> — Swan Investments — Analyst<\/em><\/p>\n

Sure. Sure. Thank you<\/p>\n

Operator<\/strong><\/p>\n

Thank you Sir, we do not have anybody in the queue right now. As there are no participants in the queue right now. I would now like to hand the conference over to the management for closing comments.<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

Thank you all for participating in this earnings call. I hope we were able to answer your questions satisfactorily. — and at the same time, offer insights into our business. If you have any further questions, I would like to know more about the company, please reach out to our Investor Relations managers at Valorem Advisors. Thank you. Stay safe, stay healthy.<\/p>\n

Operator<\/strong><\/p>\n

Sir, before we could disconnect, we have — Mr. Nikos Shetty, who is in the Q&A, wants to ask a question to you.<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

Please take.<\/p>\n

Operator<\/strong><\/p>\n

I’m unmuting your line, Mr. Nikos Shape. Please proceed.<\/p>\n

Nikos Shape<\/strong> — — Analyst<\/em><\/p>\n

Yes. Just wanted to get some clarity on pharma intermediate. So pharma intermediates, we are doing capex of INR60 crores. And you mentioned that INR50 crores revenue at a peak, which translated into asset turnover less than one times. So am I missing anything here? Or is it because of the arrangement with the group companies? And what will be the margin in this?<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

No, no, no arrangement. We’re just being conservative on the revenue side. Even though I said 50, we see an upside having some benefit there. And as far as capex is concerned, it’s somewhere around 60%, probably a little more. So all in all, on one is what would be — we believe that we will be able to have that turnover.<\/p>\n

Nikos Shape<\/strong> — — Analyst<\/em><\/p>\n

And how much margin we are expecting from this product?<\/p>\n

Mahek Manoj Chheda<\/strong> — Chief Financial Officer and Executive Director<\/em><\/p>\n

Margins — sorry, we’re not disclosing any margin level, only company level margin is what we will be able to disclose.<\/p>\n

Nikos Shape<\/strong> — — Analyst<\/em><\/p>\n

Okay. The — that’s it.Thank you.<\/p>\n

Operator<\/strong><\/p>\n

[Operator Closing Remarks]<\/p>\n","protected":false},"excerpt":{"rendered":"

Valiant Organics Ltd (NSE:VALIANTORG) Q2 FY23 earnings concall dated Nov. 10, 2022 Corporate Participants: Nikesh Shetty — Investor Relations Arvind Kanji Chheda — Managing Director and Executive Director Mahek Manoj Chheda — Chief Financial Officer and Executive Director Analysts: Varun — Kenia Capital — Analyst Adit Ketan — Smith Limited — Analyst Manish Jain — […]<\/p>\n","protected":false},"author":1905,"featured_media":71742,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[6349],"tags":[8890,8519],"class_list":["post-138016","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-transcripts","tag-basic-materials","tag-chemicals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":130726,"url":"https:\/\/alphastreet.com\/india\/aether-industries-ltd-q4-fy22-earnings-conference-call-insights\/","url_meta":{"origin":138016,"position":0},"title":"Aether Industries Ltd Q4 FY22 Earnings Conference Call Insights","author":"Praveen","date":"June 20, 2022","format":false,"excerpt":"Key highlights from Aether Industries Ltd (AETHER) Q4 FY22 Earnings Concall \u00a0 Q&A Highlights: Gagan Thareja - ASK Investment Managers - Analyst Would growth get constrained due to lack of capacity for the first 3 quarters of FY23? Rohan Desai - Whole-time Director Currently at 80% of utilization. Constantly debottlenecking\u2026","rel":"","context":"In "Concall Highlights"","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":130706,"url":"https:\/\/alphastreet.com\/india\/arvind-fashions-ltd-q4-fy22-earnings-conference-call-insights\/","url_meta":{"origin":138016,"position":1},"title":"Arvind Fashions Ltd Q4 FY22 Earnings Conference Call Insights","author":"Praveen","date":"June 20, 2022","format":false,"excerpt":"https:\/\/youtu.be\/0cA4isOv5b4 Key highlights from Arvind Fashions Ltd (ARVINDFASN) Q4 FY22 Earnings Concall \u00a0 Management Update: Despite two COVID waves, AFL grew revenues 32% and posted a net profit of INR40 crores in 2H22, and reduced net debt by more than INR525 crores in the year. With the turnaround complete, expects\u2026","rel":"","context":"In "Concall Highlights"","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":130743,"url":"https:\/\/alphastreet.com\/india\/international-conveyors-ltd-q4-fy22-earnings-conference-call-insights\/","url_meta":{"origin":138016,"position":2},"title":"International Conveyors Ltd Q4 FY22 Earnings Conference Call Insights","author":"Praveen","date":"June 21, 2022","format":false,"excerpt":"Key highlights from International Conveyors Ltd (INTLCONV) Q4 FY22 Earnings Concall \u00a0 Q&A Highlights: Muzammil Usmani \u2013 Paramount - Analyst Replacement and the new demand from the revenue generated and outlook? Prasad Deshpande \u2013 ED Each mines have their own blocks and they also explore new blocks. As on date,\u2026","rel":"","context":"In "Concall Highlights"","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":145880,"url":"https:\/\/alphastreet.com\/india\/ratnamani-metals-tubes-limited-ratnamani-q4-fy23-earnings-concall-transcript\/","url_meta":{"origin":138016,"position":3},"title":"Ratnamani Metals & Tubes Limited (RATNAMANI) Q4 FY23 Earnings Concall Transcript","author":"IRS_INDIA","date":"May 11, 2023","format":false,"excerpt":"Ratnamani Metals & Tubes Limited (NSE:RATNAMANI) Q4 FY23 Earnings Concall dated May. 11, 2023. Corporate Participants: Manoj Sanghvi\u00a0--\u00a0Business Unit Head Vimal Katta\u00a0--\u00a0Chief Financial Officer Unidentified Speaker\u00a0-- Analysts: Sahil Sanghvi\u00a0--\u00a0Monarch Networth Capital -- Analyst Noel Vaz\u00a0--\u00a0Union Mutual Fund -- Analyst Pritesh Chheda\u00a0--\u00a0Lucky Investment Managers Pvt Ltd. -- Analyst Pujan Shah\u00a0--\u00a0Congruence Advisers\u2026","rel":"","context":"In "Earnings Call Transcripts"","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"Earnings Conference Call Transcript","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":130798,"url":"https:\/\/alphastreet.com\/india\/renaissance-global-ltd-q4-fy22-earnings-conference-call-insights\/","url_meta":{"origin":138016,"position":4},"title":"Renaissance Global Ltd Q4 FY22 Earnings Conference Call Insights","author":"Praveen","date":"June 24, 2022","format":false,"excerpt":"https:\/\/youtu.be\/D5a_xmWE2AE Key highlights from Renaissance Global Ltd (RGL) Q4 FY22 Earnings Concall \u00a0 Q&A Highlights: Hitesh Chauhan - H2 Investment \u2013 Analyst China operation update? Sumit Shah \u2013 Chairman RGL tested Enchanted Disney Fine Jewellery program with a key retailer in China. The product did not perform up to expectations\u2026","rel":"","context":"In "Concall Highlights"","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":135898,"url":"https:\/\/alphastreet.com\/india\/paradeep-phosphates-ltd-paradeep-q1-fy23-earnings-concall-transcript\/","url_meta":{"origin":138016,"position":5},"title":"Paradeep Phosphates Ltd (PARADEEP) Q1 FY23 Earnings Concall Transcript","author":"IRS_INDIA","date":"August 4, 2022","format":false,"excerpt":"Paradeep Phosphates Ltd (NSE: PARADEEP) Q1 FY23 Earnings Concall dated Aug. 04, 2022 Corporate Participants: Narayanan Suresh Krishnan\u00a0--\u00a0Managing Director and Chief Executive Officer Alok Saxena\u00a0--\u00a0General Manager and Head of Corporate Finance Analysts: Anirudh Joshi\u00a0--\u00a0ICICI Securities -- Analyst Amanjit Singh\u00a0--\u00a0Oculus Capital Growth Fund -- Analyst Prashant Biyani\u00a0--\u00a0Elara Capital -- Analyst Manish\u2026","rel":"","context":"In "LATEST"","block_context":{"text":"LATEST","link":"https:\/\/alphastreet.com\/india\/category\/latest\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/138016","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1905"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=138016"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/138016\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/71742"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=138016"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=138016"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=138016"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}